|
2023 Conference Publication Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel diseaseTan, W. L., Barr, E., Pham, H., Fernandes, R., Khoo, E., An, Y-K and Begun, J. (2023). Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case reportEtchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCCFernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Gazelakis, K., Moore, G., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Lynch, K., Ngoi, B., Judge, C., Kim, D. H., Kim, H. S., Lee, H. S., Kim, K. O., Lee, Y. J., Kim, S-J, Lee, J., Song, E. M., Park, S. H. ... An, Y-K (2023). Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn's disease irrespective of previous failure to respond to biologics or conventional therapiesBegun, J., Feagan, B., Horst, S., Dryden, G., Lindsay, J., Ferrante, M., Dubcenco, E., Lacerda, A., Ford, S., Anyanwu, S., Zhou, Q., Liu, J., Chen, M. and Schreiber, S. (2023). Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn's disease irrespective of previous failure to respond to biologics or conventional therapies. HOBOKEN: WILEY. |
|
2023 Conference Publication Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitisGilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopal, K., Han, S., Bryant, R., Corte, C., Ding, J. N., An, Y-K and Begun, J. (2023). Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Fistulizing Crohn's disease in a large real-world cohort: Crohn's Colitis Cure data insights programMcnamara, J., Wilson, W., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Ng, W., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Britt, L., Verdon, C., Andrews, J. and Connor, S. (2023). Fistulizing Crohn's disease in a large real-world cohort: Crohn's Colitis Cure data insights program. HOBOKEN: WILEY. |
|
2023 Journal Article Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel diseaseEwais, Tatjana, Begun, Jakob and Laakso, E-Liisa (2023). Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel disease. Biomedicines, 11 (8) 2179, 1-11. doi: 10.3390/biomedicines11082179 |
|
2023 Journal Article Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitisGilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115 |
|
2023 Conference Publication Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitisCameron, A., Giri, R., Begun, J., Wells, T., Bergot, A. S. and Thomas, R. (2023). Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis. EULAR 2023 European Congress of Rheumatology, Milan, Italy, 31 May-3 June 2023. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2023-eular.1346 |
|
2023 Journal Article Upadacitinib induction and maintenance therapy for Crohn's diseaseLoftus, Edward V., Panés, Julian, Lacerda, Ana P., Peyrin-Biroulet, Laurent, D'Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid S., Phillips, Charles, Mohamed, Mohamed-Eslam F, Liu, Jianzhong, Geng, Ziqian, Feng, Tian, Dubcenco, Elena and Colombel, Jean-Frederic (2023). Upadacitinib induction and maintenance therapy for Crohn's disease. The New England journal of medicine, 388 (21), 1966-1980. doi: 10.1056/NEJMoa2212728 |
|
2023 Conference Publication Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora studyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Giri, Rabina, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/S0016-5085(23)02531-3 |
|
2023 Conference Publication Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora studyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Dr Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study. Digestive Disease Week DDW / AGA Conference 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)03564-3 |
|
2023 Conference Publication Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora StudyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. |
|
2023 Conference Publication WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIALPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. |
|
2023 Conference Publication Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-treated Patients With Ulcerative Colitis (Views): A Multi-centre Randomised Controlled TrialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-treated Patients With Ulcerative Colitis (Views): A Multi-centre Randomised Controlled Trial. Digestive Disease Week (DDW) 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)01488-9 |
|
2023 Conference Publication Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohortAn, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. |
|
2023 Conference Publication The interplay of IL-23, probiotic and pathobiont bacteria in the pathogenesis of ileitis and spondyloarthritis in the SKG mouse modelBergot, Anne-Sophie, Cai, Benjamin, Giri, Rabina, Cameron, Amy, Duggan, Emily, Lim, Kai, Rehaume, Linda, Morrison, Mark, Begun, Jakob and Thomas, Ranjeny (2023). The interplay of IL-23, probiotic and pathobiont bacteria in the pathogenesis of ileitis and spondyloarthritis in the SKG mouse model. 2023 Australian Rheumatology Association (ARA) 63rd Annual Scientific Meeting, Hobart, TAS, Australia, 6–9 May 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Journal Article Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liverAlabbas, Saleh Y., Giri, Rabina, Oancea, Iulia, Davies, Julie, Schreibner, Veronika, Florin, Timothy H. and Begun, Jakob (2023). Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver. Journal of Gastroenterology and Hepatology, 38 (4), 609-618. doi: 10.1111/jgh.16102 |
|
2023 Journal Article Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialFeagan, Brian G, Sands, Bruce E, Sandborn, William J, Germinaro, Matthew, Vetter, Marion, Shao, Jie, Sheng, Shihong, Johanns, Jewel, Panés, Julián, Tkachev, Alexander, Kalimullina, Dilara, Petryka, Robert, Osipenko, Marina, Tsarynna, Nataliia, Bilianskyi, Leonid, Kleczkowski, Dariusz, Yurkiv, Andrii, Woynarowski, Marek, Abrahamovych, Orest, Ivanishyn, Olha, Rydzewska, Grazyna, Kierkus, Jaroslaw, Petrova, Elina, Vasilevskaya, Olga, Afanasieva, Halyna, Francesconi, Carlos, Leszczyszyn, Jaroslaw, Bunkova, Elena, Platonov, Dmitry ... for the VEGA Study Group (2023). Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. The Lancet Gastroenterology and Hepatology, 8 (4), 307-320. doi: 10.1016/S2468-1253(22)00427-7 |
|
2023 Journal Article Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancerLyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127 |
